marketcaparena
Search

    MRKR

    Marker Therapeutics, Inc.

    Company overview

    Market capitalization
    $18.76M
    Employees
    5
    Latest publication
    2026-09-29
    About Marker Therapeutics, Inc.

    Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreatic cancer; and MT-401-OTS, which is in a Phase 1 trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company was formerly known as TapImmune, Inc. and changed its name to Marker Therapeutics, Inc. in October 2018. Marker Therapeutics, Inc. was founded in 1999 and is headquartered in Houston, Texas.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Total Revenue0USD1,103,443USD1,232,938USD861,184USD349,104USD2,251,763USD1,926,000USD1,169,236USD
    Research Development2,842,728USD2,140,832USD2,345,843USD4,177,054USD3,135,427USD5,086,184USD3,471,000USD2,335,430USD
    Selling General Administrative1,229,807USD846,606USD1,023,821USD945,163USD1,369,215USD1,026,996USD854,677USD1,141,871USD
    Total Operating Expenses4,072,535USD1,883,994USD3,369,664USD945,163USD1,822,350USD1,026,996USD854,677USD1,141,871USD
    Operating Income-4,072,535USD-1,883,994USD-2,136,726USD-4,261,033USD-4,608,673USD-3,861,417USD-2,400,000USD-2,308,065USD
    Interest Income132,889USD165,628USD138,064USD128,025USD162,489USD73,746USD91,681USD115,388USD
    Net Interest Income132,889USD165,628USD138,064USD128,025USD162,489USD73,746USD91,681USD115,388USD
    Income Before Tax-3,179,278USD-1,718,366USD-1,998,662USD-4,015,564USD-4,446,184USD-3,787,671USD-2,308,000USD-2,192,677USD
    Net Income-3,179,278USD-1,703,210USD-1,998,662USD-4,015,564USD-4,446,184USD-3,837,624USD-2,308,000USD-2,192,677USD
    Net Income From Continuing Ops-3,179,278USD-1,703,210USD-1,998,662USD-4,015,564USD-4,446,184USD-3,837,624USD-2,308,192USD-2,192,677USD
    Ebitda-4,072,535USD-1,883,994USD-1,998,666USD-4,261,030USD-4,446,184USD-3,861,420USD-2,400,000USD-2,308,000USD
    Total Other Income Expense Net893,257USD165,628USD138,064USD245,469USD162,489USD73,746USD91,681USD115,388USD
    Unclassified Operating Expenses—-1,103,444USD—-4,177,054USD-2,682,292USD-5,086,184USD-3,471,000USD-2,335,430USD
    Income Tax Expense—-15,156USD———49,953USD——
    Gross Profit——1,232,938USD-3,315,870USD-2,786,323USD-2,834,421USD-1,545,000USD-1,166,194USD
    Ebit——-1,998,662USD-4,261,033USD-8,602,000USD-3,861,417USD——
    Depreciation And Amortization——-4USD3USD4,155,538USD-3USD—2,308,065USD
    Cost Of Revenue———4,177,054USD3,135,427USD5,086,184USD3,471,000USD2,335,430USD
    Interest Expense—————437,010USD——
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Revenue3,546,669USD6,591,080USD3,311,133USD3,513,544USD1,241,710USD466,785USD213,194USD205,994USD
    Research Development11,799,154USD13,467,845USD10,416,789USD11,968,428USD27,794,879USD18,881,000USD12,764,804USD123,998,000USD
    Selling General Administrative4,184,806USD4,241,607USD7,475,722USD11,336,120USD12,925,000USD10,472,000USD9,977,196USD24,380,000USD
    Unclassified Operating Expenses-3,093,534USD-13,467,845USD-10,416,789USD-11,968,428USD-3,162,812USD-18,881,000USD-12,764,804USD—
    Total Operating Expenses12,890,426USD4,241,607USD7,475,722USD11,336,120USD37,557,067USD10,472,000USD9,977,196USD148,378,000USD
    Operating Income-12,890,426USD-11,118,372USD-14,581,378USD-19,791,004USD-39,477,995USD-28,886,000USD-22,528,806USD-148,172,000USD
    Interest Income594,206USD437,010USD447,229USD248,063USD5,700USD148,742USD1,082,842USD253,723USD
    Net Interest Income594,206USD437,010USD447,229USD248,063USD5,700USD148,742USD1,082,842USD253,723USD
    Income Before Tax-12,178,776USD-10,681,362USD-14,042,220USD-19,775,915USD-41,878,871USD-28,706,000USD-21,427,964USD-147,958,000USD
    Income Tax Expense-15,156USD49,953USD3,675USD-15,089USD-5,700USD-180,000USD-1,101,000USD-214,000USD
    Tax Provision-15,156USD49,953USD3,675USD0USD————
    Net Income-12,163,620USD-10,731,315USD-8,236,814USD-29,930,694USD-41,878,871USD-28,706,000USD-21,427,964USD-147,958,000USD
    Net Income From Continuing Ops-12,163,620USD-10,731,315USD-24,503,900USD-29,930,694USD-41,878,871USD-28,706,070USD-21,427,964USD-147,957,910USD
    Ebitda-12,437,291USD-11,118,370USD-11,792,272USD-17,001,898USD-38,716,233USD-27,630,000USD-22,423,683USD-147,966,000USD
    Total Other Income Expense Net711,650USD437,010USD539,158USD15,089USD-2,400,876USD179,742USD1,100,842USD213,723USD
    Cost Of Revenue—13,467,845USD10,416,789USD11,968,428USD3,162,638USD18,881,000USD12,764,804USD123,998,000USD
    Gross Profit—-6,876,765USD-7,105,656USD-8,454,884USD-1,920,928USD-18,414,000USD-12,551,610USD-123,792,000USD
    Ebit—-11,118,372USD-14,581,378USD-19,791,004USD-41,878,871USD-28,706,000USD-22,528,806USD-296,138,000USD
    Depreciation And Amortization—2USD2,789,106USD2,789,106USD3,162,638USD1,076,000USD105,123USD148,172,000USD
    Interest Expense———15,089USD5,700USD148,742USD0USD0USD
    Reconciled Depreciation———3,680,449USD3,162,638USD1,075,680USD286,582USD—
    Net Income Applicable To Common Shares————-41,878,871USD-28,706,070USD-21,427,964USD-147,957,910USD
    Non Operating Income Net Other—————179,742USD1,100,842USD213,723USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets14,585,485USD17,434,008USD19,070,997USD21,734,830USD14,767,870USD16,993,266USD22,022,860USD10,910,348USD
    Cash And Equivalents11,331,023USD———————
    Total Current Assets14,585,485USD17,434,008USD19,070,997USD21,734,830USD14,767,870USD16,993,266USD22,022,860USD10,910,348USD
    Other Current Assets7,203USD1,141,189USD3,002,947,631,000USD2,479,699USD2,631,564USD841,293USD483,717USD1,166,274USD
    Total Liabilities2,420,021USD———————
    Total Current Liabilities2,420,021USD3,638,050USD22,741,830USD3,345,937USD4,277,477USD2,501,395USD3,464,454USD3,460,773USD
    Other Current Liabilities804,795USD———————
    Total Stockholder Equity12,165,464USD13,795,958USD16,796,814USD18,388,893USD10,490,393USD14,491,871USD18,558,406USD7,449,575USD
    Total Equity Including Noncontrolling Interest12,165,464USD———————
    Accounts Payable585,039USD1,500,256USD793,727USD951,000USD1,715,000USD1,297,000USD1,066,000USD1,904,000USD
    Common Stock16,672USD16,672USD16,672USD16,672USD11,313USD11,213USD10,708USD8,923USD
    Retained Earnings-464,186,305USD-462,360,076USD-459,180,798USD-457,477,588USD-455,478,926USD-451,463,362USD-447,017,178USD-443,179,554USD
    Total Liab—3,638,050USD22,741,830USD3,345,937USD4,277,477USD2,501,395USD3,464,454USD3,460,773USD
    Other Current Liab—1,414,658USD1,299,383,206,638USD1,041,962USD1,146,502USD1,062,395USD2,294,454USD1,556,773USD
    Capital Stock—16,672USD16,672USD16,672USD11,313USD11,213USD10,708USD8,923USD
    Cash—14,915,519USD16,068,048USD17,589,978USD10,461,971USD13,693,208USD19,192,440USD8,999,664USD
    Cash And Short Term Investments—14,915,519USD16,068,048USD17,589,978USD10,461,971USD13,693,208USD19,192,440USD8,999,664USD
    Current Deferred Revenue—723,136USD974,799USD1,352,975USD1,352,975USD———
    Net Debt—-14,915,519USD-16,068,048USD-17,589,978USD-10,461,971USD-13,693,208USD-19,192,440USD-8,999,664USD
    Net Receivables—1,377,300USD1,369,000USD1,665,153USD1,674,335USD2,458,765USD2,346,703USD744,410USD
    Common Stock Shares Outstanding—19,314,742shares15,310,000shares16,757,678shares13,956,562shares11,106,000shares9,101,000shares8,923,000shares
    Non Current Assets Total—0USD0USD0USD0USD0USD0USD0USD
    Non Current Liabilities Total—0USD0USD0USD0USD0USD0USD0USD
    Net Working Capital—13,795,958USD16,796,814USD18,388,893USD10,490,393USD14,491,871USD18,558,406USD7,449,575USD
    Unclassified Equity—476,122,690USD475,944,268USD475,833,137USD465,946,693USD465,932,807USD465,554,168USD450,611,283USD
    Unclassified Current Assets——-3,002,945,997,051USD———-19,192,420,807,560USD—
    Unclassified Current Liabilities——-1,299,362,233,334USD—————
    Short Term Investments——————19,192,420,807,560USD—
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets19,070,997USD22,022,860USD17,127,391USD34,422,184USD68,135,134USD45,614,815USD46,359,282USD62,144,310USD
    Other Current Assets3,002,947,631,000USD483,717USD1,976,252USD2,435,079USD3,630,820USD2,057,924USD1,526,442USD283,434USD
    Total Liab22,741,830USD3,464,454USD3,074,848USD14,821,147USD24,149,539USD18,270,242USD2,273,059USD2,803,572USD
    Total Stockholder Equity16,796,814USD18,558,406USD14,052,543USD19,601,037USD43,985,595USD27,344,573USD44,086,223USD59,340,738USD
    Other Current Liab1,299,383,206,638USD2,294,454USD1,894,848USD3,603,611USD5,990,913USD3,078,010USD795,680USD1,184,572USD
    Common Stock16,672USD10,708USD8,891USD8,406USD8,308USD50,731USD45,728USD45,440USD
    Capital Stock16,672USD10,708USD8,891USD8,406USD83,079USD50,731USD45,728USD45,440USD
    Retained Earnings-459,180,798USD-447,017,178USD-436,285,863USD-428,049,049USD-398,118,355USD-356,239,484USD-327,533,414USD-306,105,450USD
    Cash16,068,048USD19,192,440USD15,111,450USD11,782,172USD42,351,145USD21,352,382USD43,903,949USD61,746,748USD
    Cash And Short Term Investments16,068,048USD19,192,440USD15,111,450USD11,782,172USD42,351,145USD21,352,382USD43,903,949USD61,746,748USD
    Total Current Assets19,070,997USD22,022,860USD17,127,391USD16,619,255USD45,982,202USD24,410,865USD45,486,580USD61,996,642USD
    Total Current Liabilities22,741,830USD3,464,454USD3,074,848USD7,781,809USD12,901,589USD6,401,802USD1,992,812USD2,803,572USD
    Current Deferred Revenue974,799USD——2,500,000USD1,146,186USD3,078,000USD765,000USD—
    Net Debt-16,068,048USD-19,192,440USD-15,111,450USD-4,165,636USD-30,482,705USD-9,095,150USD-43,419,570USD-61,746,748USD
    Net Receivables1,369,000USD2,346,703USD1,027,815USD2,402,004USD237USD1,000,559USD56,189USD108,177USD
    Accounts Payable793,727USD1,066,000USD961,000USD1,101,000USD5,144,000USD2,935,000USD993,000USD1,619,000USD
    Common Stock Shares Outstanding15,310,000shares8,980,000shares8,809,000shares8,351,000shares7,651,000shares4,704,000shares4,559,000shares1,909,000shares
    Non Current Assets Total0USD0USD0USD17,802,929USD22,153,071USD21,204,214USD872,702USD148,000USD
    Non Current Liabilities Total0USD0USD0USD7,039,338USD11,247,950USD11,868,440USD280,246USD1,619,000USD
    Net Working Capital16,796,814USD18,558,406USD14,052,543USD8,837,446USD33,080,613USD18,009,063USD43,493,768USD59,193,070USD
    Unclassified Current Assets-3,002,945,997,051USD-19,192,420,807,560USD——————
    Unclassified Current Liabilities-1,299,362,233,334USD————-3,078,000USD——
    Unclassified Equity475,944,268USD465,554,168USD450,320,624USD447,633,274USD442,012,563USD383,482,595USD371,633,181USD365,355,308USD
    Short Term Investments—19,192,420,807,560USD——————
    Inventory——-988,126USD——-1,000,000USD——
    Short Term Debt———577,198USD620,490USD388,792USD204,132USD49,000USD
    Short Long Term Debt Total———7,616,536USD11,868,440USD12,257,232USD484,379USD—
    Property Plant Equipment Net———17,802,786USD22,153,071USD21,204,214USD872,702USD148,000USD
    Property Plant Equipment Gross———17,802,929USD24,893,071USD21,204,214USD873,174USD148,000USD
    Non Currrent Assets Other———143USD2,225,610USD-21,203,950USD-472USD-332USD
    Unclassified Non Current Liabilities———7,039,338USD11,247,950USD——1,619,000USD
    Other Assets————-139USD-264USD-472USD-332USD
    Net Tangible Assets————43,985,595USD27,344,573USD44,086,223USD59,340,738USD
    Unclassified Non Current Assets————-2,225,610USD———
    Non Current Liabilities Other—————11,868,440USD280,247USD—
    Accumulated Other Comprehensive Income——————-105,000USD—
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Stock Based Compensation374,157USD
    Change To Liabilities-275,467USD
    Change In Working Capital-275,467USD
    Operating Cash Flow-5,120,515USD
    Change In Cash-5,120,515USD
    End Cash Flow11,922,332USD
    SourceDisclosureDeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income-3,179,278USD-1,703,210USD-1,998,662USD-4,015,564USD-4,446,184USD-3,837,624USD-2,308,192USD-2,192,677USD
    Stock Based Compensation178,422USD111,131USD33,279USD13,986USD379,144USD50,544USD53,302USD62,601USD
    Other Non Cash Items178,422USD-388,001,611,000USD33,279USD——-916,055USD53,302USD971,314USD
    Change To Account Receivables-7,900USD295,753USD9,182USD784,430USD-112,062USD-1,602,293USD1,745,737USD-638,685USD
    Change In Working Capital1,596,664USD-308,027USD-770,493USD2,123,216USD-1,432,697USD-916,055USD3,452,389USD-1,437,494USD
    Total Cash From Operating Activities-1,404,192USD-1,900,106USD-2,735,876USD-1,878,362USD-5,499,737USD-4,703,135USD1,197,499USD-3,567,570USD
    Capital Expenditures-2USD0USD-4USD0USD-3USD-5USD-1USD0USD
    Free Cash Flow-1,404,190USD-1,900,106USD-2,735,880USD-1,878,362USD-5,499,737USD-4,703,135USD1,197,500USD-3,567,570USD
    Total Cash From Financing Activities0USD9,864,478,136,000USD9,863,883USD100USD505USD14,895,911USD1,701USD44,606USD
    Change In Cash-1,404,192USD-1,900,106USD7,128,007USD-1,878,262USD-5,499,232USD10,192,776USD1,199,200USD-3,522,964USD
    Begin Period Cash Flow17,042,847USD18,942,953USD11,814,946USD13,693,208USD19,192,440USD8,999,664USD7,800,464USD11,323,428USD
    End Period Cash Flow15,638,655USD17,042,847USD18,942,953USD11,814,946USD13,693,208USD19,192,440USD8,999,664USD7,800,464USD
    Issuance Of Capital Stock—0USD9,863,883USD——14,892,253USD0USD36,902USD
    Other Cashflows From Financing Activities—9,864,478,136,000USD9,863,883USD100USD505USD3,658USD1,701USD7,704USD
    Unclassified Operating Cash Flow—388,001,611,000USD——————
    Unclassified Financing Cash Flow——-9,863,883USD—————
    Investments—————0USD0USD0USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income-12,163,620,000,000USD-10,731,315USD-14,045,895USD-19,775,915USD-41,878,871USD-28,706,070USD-21,427,964USD-147,957,910USD
    Stock Based Compensation537,540,000,000USD245,864USD858,269USD3,304,634USD5,964,048USD5,228,409USD5,356,972USD16,350,592USD
    Other Non Cash Items-388,000,611,999USD-11,156,176,843,812USD-6,098,899USD-2,432,722USD7,147,588USD-31,000USD-18,000USD116,084,886USD
    Change To Account Receivables977,303USD-1,318,888USD1,374,189USD-2,401,767USD1,000,322USD55,630USD51,988USD55,630USD
    Change In Working Capital-388,000USD-424,873USD2,846,564USD-4,763,516USD5,472,420USD2,398,290USD-2,481,883USD1,042,516USD
    Total Cash From Operating Activities-12,014,081,000,000USD-10,910,324USD-16,439,961USD-26,972,153USD-27,279,765USD-20,034,691USD-18,284,293USD-14,479,916USD
    Capital Expenditures0USD0USD-1USD-3USD-3,131,131USD-9,252,887USD-374,987USD-147,668USD
    Free Cash Flow-12,014,081,000,000USD-10,910,324USD-16,439,961USD-26,972,150USD-30,410,896USD-29,287,578USD-18,659,280USD-14,627,584USD
    Total Cash From Financing Activities9,864,488,000,000USD14,991,314USD1,105,117USD202,130USD52,555,845USD6,736,011USD816,477USD71,245,043USD
    Issuance Of Capital Stock9,863,883USD14,929,155USD1,153,197USD202,130USD52,552,758USD6,186,011USD0USD66,945,000USD
    Change In Cash-2,149,593,000,000USD4,080,990USD3,329,278USD-31,715,159USD22,144,949USD-22,551,567USD-17,842,799USD56,617,459USD
    Begin Period Cash Flow19,192,440,000,000USD15,111,450USD11,782,172USD43,497,331USD21,352,382USD43,903,949USD61,746,748USD5,129,289USD
    End Period Cash Flow17,042,847,000,000USD19,192,440USD15,111,450USD11,782,172USD43,497,331USD21,352,382USD43,903,949USD61,746,748USD
    Other Cashflows From Financing Activities9,864,478,135,512USD62,159USD90,477USD-4,945,136USD3,087USD550,000USD816,477USD4,371,753USD
    Investments—0USD18,536,780USD-4,945,136USD-3,131,131USD-10,427,947USD-374,983USD-147,668USD
    Unclassified Operating Cash Flow—11,156,176,843,812USD—-6,985,083USD-7,147,588USD———
    Total Cashflows From Investing Activities——18,664,122USD-4,945,136USD-3,131,131USD-9,252,887USD-374,983USD-147,668USD
    Other Cashflows From Investing Activities——18,664,122USD-4,945,136USD-1,558,970USD-6,789,098USD——
    Unclassified Investing Cash Flow——-18,536,779USD4,945,139USD4,690,101USD17,217,045USD——
    Depreciation———3,680,449USD3,162,638USD1,075,680USD286,582USD286,582USD
    Change To Inventory———2,401,767USD-1,000,321USD-55,630USD-51,988USD—
    Unclassified Financing Cash Flow———4,945,136USD———66,945,000USD
    Change To Liabilities————5,287,600USD4,222,470USD-963,967USD1,241,260USD
    Sale Purchase Of Stock—————6,736,011USD816,477USD-71,710USD
    Cash And Cash Equivalents Changes—————-22,551,567USD-17,842,799USD56,617,459USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q1 2026Quarterly · 2026-03-31ProductCancer Prevention And Research Institute Of Texas Acute Myeloid Leukemia208,509USD0001104659-26-062763
    Q1 2026Quarterly · 2026-03-31ProductCprit Pancreatic Grant251,663USD0001104659-26-062763
    Q1 2026Quarterly · 2026-03-31ProductFda Grant2,903USD0001104659-26-062763
    Q1 2026Quarterly · 2026-03-31ProductNational Institutes Of Health National Cancer Institute Grant98,634USD0001104659-26-062763
    Q1 2026Quarterly · 2026-03-31ProductNational Institutes Of Health Small Business Innovation Research116,504USD0001104659-26-062763
    Q1 2026Quarterly · 2026-03-31ProductNational Institutes Of Health Small Business Innovation Research For Pancreatic Cancer73,478USD0001104659-26-062763
    FY 2025Yearly · 2025-12-31ProductCprit Pancreatic Grant573,994USD0001104659-26-031274
    FY 2025Yearly · 2025-12-31ProductFda Grant118,478USD0001104659-26-031274
    FY 2025Yearly · 2025-12-31ProductGrant — Cancer Prevention And Research Institute Of Texas Acute Myeloid Leukemia900,014USD0001104659-26-031274
    FY 2025Yearly · 2025-12-31ProductGrant — National Institutes Of Health Small Business Innovation Research472,208USD0001104659-26-031274
    FY 2025Yearly · 2025-12-31ProductGrant — National Institutes Of Health Small Business Innovation Research For Pancreatic Cancer425,670USD0001104659-26-031274
    FY 2025Yearly · 2025-12-31ProductNational Institutes Of Health National Cancer Institute Grant391,305USD0001104659-26-031274
    FY 2025Yearly · 2025-12-31ProductNational Institutes Of Health Small Business Innovation Research For Lymphoma Grant665,000USD0001104659-26-031274
    Q1 2025Quarterly · 2025-03-31ProductCancer Prevention And Research Institute Of Texas Acute Myeloid Leukemia217,641USD0001104659-26-062763
    Q1 2025Quarterly · 2025-03-31ProductCprit Pancreatic Grant12,544USD0001104659-26-062763
    Q1 2025Quarterly · 2025-03-31ProductNational Institutes Of Health National Cancer Institute Grant14,216USD0001104659-26-062763
    Q1 2025Quarterly · 2025-03-31ProductNational Institutes Of Health Small Business Innovation Research96,724USD0001104659-26-062763
    Q1 2025Quarterly · 2025-03-31ProductNational Institutes Of Health Small Business Innovation Research For Pancreatic Cancer7,979USD0001104659-26-062763
    FY 2024Yearly · 2024-12-31ProductFda Grant519,750USD0001104659-26-031274
    FY 2024Yearly · 2024-12-31ProductGrant — Cancer Prevention And Research Institute Of Texas Acute Myeloid Leukemia4,411,149USD0001104659-26-031274
    FY 2024Yearly · 2024-12-31ProductGrant — National Institutes Of Health Small Business Innovation Research982,182USD0001104659-26-031274
    FY 2024Yearly · 2024-12-31ProductGrant — National Institutes Of Health Small Business Innovation Research For Pancreatic Cancer7,177USD0001104659-26-031274
    FY 2024Yearly · 2024-12-31ProductNational Institutes Of Health National Cancer Institute Grant5,822USD0001104659-26-031274
    FY 2024Yearly · 2024-12-31ProductNational Institutes Of Health Small Business Innovation Research For Lymphoma Grant665,000USD0001104659-26-031274
    Q3 2022Quarterly · 2022-09-30ProductGrant999,571USD0001410578-22-003131
    Q3 2022Quarterly · 2022-09-30ProductServices2,950,000USD0001410578-22-003131

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.